Lyfegen, which provides a platform for value-based contracting for high-cost drugs, has announced that it has raised $8 million in Series A funding.
The round was led by aMoon, with participation from APEX Ventures and other investors. The start-up, headquartered in Switzerland and the US, provides software aimed at helping pharmaceutical companies, payers, suppliers and medical technology companies adopt contracts based on value. It includes a library of contracts, tools to simulate how models will behave before implementing them, and data collection to track performance and results.
Girisha Fernando, CEO and founder of Lyfegen, said: “We are currently working with government payers and health insurers in Europe, the US and the Middle East, and several largest pharmaceutical company in the world”.
“Our plan now is to further expand our presence in the US, working with private and public health insurers. to value-based contracts.”
Smart stethoscope company Eko received a $2.7 million grant from the National Institutes of Health to develop a machine learning algorithm that detects and classifies pulmonary hypertension.
The Small Business Innovation Research (SBIR) The Phase II Direct Grant will go towards an algorithm that uses electrocardiogram (PCG) and electrocardiogram (ECG) data collected by Eko’s stethoscope to find Pulmonary arterial hypertensionor high blood pressure, which affects the arteries in the lungs and right side of the heart.
Eko previously partnered with Lifespan Health System’s Cardiovascular Institute to collect real-world ECG and PCG data that will be part of the algorithm’s development.
“The main objective of this study was to determine whether the Eko algorithm based on cardiac recording combined with an electrocardiogram could determine the presence and severity of pulmonary hypertension when compared with current gold standard,” said Dr Gaurav Choudhary, principal investigator and chief cardiologist. Research at Lifespan Heart Institute.
“This machine learning algorithm has the potential to be a sustainable, easy-to-deploy and low-cost medical technology that helps healthcare professionals identify more patients with pulmonary arterial hypertension. “
Eko said this is their fourth SBIR grant. Recent company received FDA license 510(k) for an algorithm to detect and characterize heart murmurs in adult and pediatric patients.
Halo, which provides a platform aimed at connecting companies and scientists for research and development, has raised $2.6 million in seed funding.
Participants in this round include Asymmetric Capital Partners, Village Global, AirAngels, 23andMe co-founder and CEO Anne Wojcicki, Superhuman email client co-founder and CTO Conrad Irwin, and Rachel Hepworth, the company’s head of marketing. Notion organization software company.
The platform allows biological, medical device, consumer goods and agriculture companies to post requests for proposals for specific needs or open calls around common research interests. Scientists can then respond to their proposals, and companies can select researchers for partnerships.
Halo plans to use the seed to hire new workers, develop new collaboration features on the platform, and expand its network of scientists.
“Collaboration in R&D is as much about relationships as it is about research itself. However, companies still rely on activities that don’t scale, such as listening to a talk at a conference or read a magazine article This limits the business to a handful, Kevin Leland, founder and CEO of Halo, said in a statement.
“Halo connects corporate R&D teams directly with scientists. Through our platform, we designed the ability to fortuitously so that companies can quickly and easily find companies new technologies, expand their networks globally, and build relationships with scientists year-round.”